FATE THERAPEUTICS INC

FATE THERAPEUTICS INC insiders are currently net buyers of FATE stock, showing neutral sentiment over the past 90 days. Executives have purchased $162.6M while selling $129.1M, resulting in a positive net flow of $33.5M. This buying activity represents 56% of total transaction volume.

FATE THERAPEUTICS INC has 33 active insiders who have filed SEC Form 4 transactions in the past 90 days. Jeremy Green (Executive) leads with 15 transactions totaling $154.8M. Group, Llc Redmile (Executive) follows with 7 transactions worth $80.5M. Open-market purchases require insiders to invest their own capital, demonstrating genuine conviction.

The Insider Alignment Score measures the ratio of buying to selling activity on a 0-100 scale. FATE THERAPEUTICS INC's current score of 56/100 indicates neutral insider sentiment. Scores between 40-60 represent neutral or mixed activity. With $162.6M in purchases and $129.1M in sales, no strong directional conviction is evident.

The most recent insider transaction occurred on Jan 9, 2026, when Valamehr Bahram (Executive) disposed of 5,190 shares at $1.07 per share for $5.6K. This appears to be a discretionary trade.

Based on SEC Form 4 filings from the past 90 days, FATE insider trading sentiment is currently neutral with an Alignment Score of 56/100. The balanced activity—$162.6M bought vs $129.1M sold—suggests no strong consensus among insiders.

SEC Form 4 is the primary disclosure mechanism for insider trading at publicly traded companies like FATE THERAPEUTICS INC. Corporate insiders must file within two business days of any transaction, making it one of the most timely sources of executive sentiment. At FATE, we track all Form 4 filings—currently showing 636 transactions from 33 insiders over 90 days.

A 10b5-1 plan allows FATE THERAPEUTICS INC executives to pre-schedule stock sales when they don't possess material non-public information. At FATE, approximately 22% of recent transactions are 10b5-1 trades. The remaining 78% are discretionary trades, which may carry more informational value.

You can monitor FATE THERAPEUTICS INC (FATE) insider trading activity on this page, which updates within hours of new SEC Form 4 filings. We track all 33 active insiders and provide real-time transaction feeds, the Alignment Score, 10b5-1 vs. discretionary breakdowns, and direct links to SEC EDGAR filings.

Our Alignment Score measures the ratio of insider buying to selling on a scale of 0-100. A score above 70 indicates strong bullish sentiment, while below 30 suggests bearish activity. FATE THERAPEUTICS INC's current score of 56/100 indicates neutral sentiment with balanced buying and selling activity. This is calculated from $162.6M in purchases versus $129.1M in sales over 90 days, resulting in a net flow of $33.5M.

SEC Form 4 filings are mandatory reports that FATE THERAPEUTICS INC insiders must submit within 2 business days. Each filing includes the insider's name, relationship, transaction type, shares, and price. Transaction codes: P (purchase), S (sale), A (award), M (option exercise), G (gift). At FATE, the most common type is "S" with 22 occurrences. The most recent Form 4 was filed on Jan 9, 2026 by Valamehr Bahram.

Rule 10b5-1 allows corporate insiders to establish pre-scheduled trading plans when they don't possess material non-public information. At FATE THERAPEUTICS INC, approximately 22% of recent transactions are executed under 10b5-1 plans, while 78% appear to be discretionary trades. This mix provides a balanced picture—some planned, others reflecting real-time decisions.